Revive Therapeutics Proposes Innovative Financing Strategy
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R) is making an exciting move to strengthen its financial standing by proposing a private placement offering. This initiative involves the arrangement of up to 30,952,381 units priced at $0.021 per unit, generating up to $650,000 in gross proceeds. Additionally, Revive plans to settle a debt of $67,400 through the issuance of approximately 3,209,523 units, aligning with the same pricing structure of the private placement.
Structure of the Private Placement
Each unit in the private placement comprises one common share and one common share purchase warrant. The warrant allows the holder to buy one common share at an exercise price of $0.05 for a period of 36 months following the closing. The pricing is informed by the 20-day volume weighted average price (VWAP) of trading shares on the Canadian Securities Exchange (CSE) as the company sought price protection.
Purpose and Applications of Funds
The money raised through this private placement will be dedicated to working capital, enabling the company to manage its trade payables more effectively. By issuing securities instead of utilizing cash reserves, Revive aims to preserve its financial flexibility for ongoing operations and future innovations.
Anticipated Closings and Conditions
Completion of both the private placement and the debt settlement is contingent on customary closing conditions, and the company is eager to finalize these transactions as promptly as possible. It’s important to note that all securities issued will be subject to a hold period lasting four months and one day post-issuance.
About Revive Therapeutics Ltd.
Revive Therapeutics specializes in developing innovative therapies to address significant medical needs. The company is strategically focused on its drug development pipeline, leveraging regulatory incentives from the FDA such as Emergency Use Authorizations, Orphan Drug designations, and Breakthrough Therapy classifications. This strategy aims for rapid development and market entry.
Innovative Research and Development
Currently, Revive is concentrating on exploring Bucillamine's potential against infectious diseases and undergoing significant breakthroughs in counteracting nerve agent exposure. In addition, the company is making strides with its Psilocybin and molecular hydrogen programs, venturing into new territories in medical science and offering hope for various therapeutic applications.
Stay Updated with Revive Therapeutics
Revive encourages those interested in their ongoing projects and innovations to explore more about the company via its website: www.ReviveThera.com.
How to Get in Touch
For any inquiries, interested parties can reach out to:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Frequently Asked Questions
What is the purpose of the private placement proposed by Revive?
The private placement aims to raise funds for working capital and to manage trade payables effectively while preserving cash for ongoing operations.
How much is Revive aiming to raise through this placement?
Revive is looking to raise up to $650,000 through the offering of approximately 30,952,381 units.
What will the funds from this placement be used for?
The raised funds are designated for working capital and payment of certain trade payables to enhance the company's financial health.
What does each unit in the private placement include?
Each unit consists of one common share and one common share purchase warrant, allowing the holder to buy one common share at a specified exercise price.
Who can I contact for more information about Revive Therapeutics?
For further inquiries, contact Michael Frank, CEO of Revive Therapeutics, via email at mfrank@revivethera.com or by phone at 1 888 901 0036.
